Summary
Patients with metastatic or recurrent adenocarcinoma of the breast were randomized to weekly combination chemotherapy, intermittent combination chemotherapy, or singledrug chemotherapy administered sequentially. Patients receiving weekly combination therapy were more likely to respond than those receiving single-drug therapy (5-fluorouracil). The median survival for either group treated with combination therapy was double that of patients on sequential therapy. One-fourth of the patients had a prolonged survival (>75 weeks), regardless of therapy.
This investigation was supported by the following USPHS Research Grants from the National Cancer Institute to the following institutions: CA03227 and CA11263 to Emory University School of Medicine, Atlanta, Ga.; CA06807 to Medical College of Georgia, Augusta, Ga.; CA05641 to University of Miami School of Medicine, Miami, Fla.; CA12639 to Presbyterian-University of Pennsylvania Medical Center, Philadelphia, Pa.; CA07961 to Temple University School of Medicine, Philadelphia, Pa.; CA03376 to Washington University School of Medicine, St. Louis, Mo.; CA12223 to University of Puerto Rico School of Medicine, San Juan, Puerto Rico; CA13237 to University of Tennessee Memorial Research Center, Knoxville, Tenn.; CA13249 to Veterans Administration Hospital, New Orleans, La.; CA15584 to Case Western Reserve School of Medicine-Veterans Administration Hospital, Cleveland, Ohio; CA17027 to University of Tennessee School of Medicine, Memphis, Tenn; CA17214 to St. Louis University School of Medicine, St. Louis, Mo.; and CA116389 to University of Louisville School of Medicine, Louisville, Ky.
